Neoadjuvant Chemotherapy with Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: the Randomized, Phase III OPTICAL Trial
Huabin Hu,Jianwei Zhang,Yunfeng Li,Xiaozhong Wang,Ziqiang Wang,Hui Wang,Liang Kang,Ping Liu,Ping Lan,Xiaojian Wu,Yunhuan Zhen,Haiping Pei,Zhongcheng Huang,Hao Zhang,Wenbin Chen,Yongming Zeng,Jiajun Lai,Hongbo Wei,Xuefeng Huang,Jiansi Chen,Jigui Chen,Kaixiong Tao,Qingwen Xu,Xiang Peng,Junlin Liang,Guanfu Cai,Kefeng Ding,Zhijie Ding,Ming Hu,Wei Zhang,Bo Tang,Chuyuan Hong,Jie Cao,Zonghai Huang,Wuteng Cao,Fangqian Li,Xinhua Wang,Chao Wang,Yan Huang,Yandong Zhao,Yue Cai,Jiayu Ling,Xiaoyu Xie,Zehua Wu,Lishuo Shi,Li Ling,Hao Liu,Jianping Wang,Meijin Huang,Yanhong Deng
DOI: https://doi.org/10.1200/jco.23.01889
IF: 45.3
2024-01-01
Journal of Clinical Oncology
Abstract:PURPOSE The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery. PATIENTS AND METHODS OPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat ≥5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population. RESULTS Between January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77]). CONCLUSION NAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.